Significant achievements have been made in treating advanced ccRCC in the last two decades, such as the application of tyrosine kinase and mammalian target of rapamycin (mTOR) inhibitors or monoclonal antibodies against vascular endothelial growth factor (VEGF) (5, 6). Here, MTOR is linked to nonpapillary renal cell carcinoma.